ProShares UltraShort NASDAQ Biotechnology
11 hedge funds and large institutions have $4.23M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.85% less ownership
Funds ownership: 8.49% → 7.64% (-0.85%)
15% less funds holding
Funds holding: 13 → 11 (-2)
18% less capital invested
Capital invested by funds: $5.17M → $4.23M (-$939K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$418K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$396K |
| 3 |
CT
CMT Trading
Chicago,
Illinois
|
+$223K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$145K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$495K |
| 2 |
HF
HRT Financial
New York
|
-$411K |
| 3 |
FAM
Fred Alger Management
New York
|
-$245K |
| 4 |
Morgan Stanley
New York
|
-$110K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$104K |
BIS Hedge Fund Activity: Q1 2017 in Review
11 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2017, worth a combined $4.23M — down 18% from $5.17M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BIS and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Jane Street, adding an estimated $418K. The largest seller was Susquehanna International Group, cutting an estimated $495K.
- 11 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2017, down from 13 in Q4 2016.
- Funds reported $4.23M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2017, down 18% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2017 and 4 closed out, a net change of -2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2017 was Jane Street, an estimated $418K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2017 was Susquehanna International Group, an estimated $495K sold.
Based on aggregated 13F filings for Q1 2017.